Acrivon nets ~$130M in PIPE; shares at $8.50, pre-funded warrants for 7.1M shares

Acrivon Therapeutics, Inc.

Gross proceeds ~$130M from 8.235M shares at $8.50/share and 7.06M pre-funded warrants at $8.499/warrant.
Pre-funded warrants exercisable at $0.001/share, immediately exercisable, no expiration.
Investors include RA Capital, Perceptive Advisors, Paradigm BioCapital, Surveyor Capital, Sands Capital, Acorn Bioventures.
Proceeds to fund ACR-368 registrational trials, ACR-2316, cell cycle program, AP3 platform, AI/ML; cash runway into H2 2026.
Closing expected April 11, 2024; Jefferies acted as sole placement agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.